PRKACA and neoplasm: In conjunction with the detection of a recurrent, potentially pathognomonic fusion event in FLC, but not in cHCC (DNAJB1-PRKACA) [12], and in accordance with previous reports [34,35,36], all of these observations suggest that cHCC and FLC tumours do represent different entities with different biological background, manifestation, and clinical course, and thus, require distinct therapeutic handling (s.